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Abstract
Introduction
Neuroblastoma is a malignant pediatric cancer derived from neural crest cells. It is charac-
terized by a generalized reduction of mitochondrial oxidative phosphorylation. The goal of
the present study was to investigate the effects of calorie restriction and ketogenic diet on
neuroblastoma tumor growth and monitor potential adaptive mechanisms of the cancer’s
oxidative phosphorylation system.
Methods
Xenografts were established in CD-1 nude mice by subcutaneous injection of two neuro-
blastoma cell lines having distinct genetic characteristics and therapeutic sensitivity [SH-
SY5Y and SK-N-BE(2)]. Mice were randomized to four treatment groups receiving standard
diet, calorie-restricted standard diet, long chain fatty acid based ketogenic diet or calorie-re-
stricted ketogenic diet. Tumor growth, survival, metabolic parameters and weight of the mice
were monitored. Cancer tissue was evaluated for diet-induced changes of proliferation indi-
ces and multiple oxidative phosphorylation system parameters (respiratory chain enzyme
activities, western blot analysis, immunohistochemistry and mitochondrial DNA content).
Results
Ketogenic diet and/or calorie restriction significantly reduced tumor growth and prolonged sur-
vival in the xenograft model. Neuroblastoma growth reduction correlated with decreased
blood glucose concentrations and was characterized by a significant decrease in Ki-67 and
phospho-histone H3 levels in the diet groups with low tumor growth. As in human tumor tis-
sue, neuroblastoma xenografts showed distinctly lowmitochondrial complex II activity in com-
bination with a generalized low level of mitochondrial oxidative phosphorylation, validating the
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tumor model. Neuroblastoma showed no ability to adapt its mitochondrial oxidative phosphor-
ylation activity to the change in nutrient supply induced by dietary intervention.
Conclusions
Our data suggest that targeting the metabolic characteristics of neuroblastoma could open
a new front in supporting standard therapy regimens. Therefore, we propose that a ketogen-
ic diet and/or calorie restriction should be further evaluated as a possible adjuvant therapy
for patients undergoing treatment for neuroblastoma.
Introduction
Neuroblastoma (NB) is the most common extra-cranial solid malignancy of childhood. This
tumor of the peripheral nervous system originates from primitive sympathogonia that normal-
ly give rise to the postganglionic neurons of the sympathetic chain and the adrenal medulla [1].
Based on biological and clinical features, the disease can be classified into three risk categories.
In the high-risk patient population, despite extensive efforts to improve treatment strategies,
the prognosis is poor, with an estimated 5-year survival of 50%. This contrasts to an overall
survival rate exceeding 90% in the intermediate- and low-risk groups, where treatment optimi-
zation has shifted toward reducing the toxicities of the multi-modal therapy approach [2].
The mitochondrial energy metabolism of NB is characterized by generalized low protein
and activity levels of the oxidative phosphorylation (OXPHOS) complexes, along with a low
copy number of the mitochondrial genome (mtDNA). Mitochondrial mass, however, as quan-
tified by markers such as citrate synthase activity and voltage-dependent ion channel (VDAC)
protein content, is similar to that of normal adrenal gland and kidney tissues [3]. Although the
mechanisms inducing this phenotype are still under investigation, data indicate that it is part
of the metabolic reprogramming of NB cells that permits the state of low differentiation and
high proliferative capacity. Changes in mitochondrial function have been shown to be a central
component of the induction of differentiation in NB cell lines. Retinoic acid treatment, for in-
stance, significantly increases basal oxygen consumption as well as respiratory capacity [4–6].
These observations are in line with the reprogramming of cancer cell metabolism to increased
glucose utilization, one of the hallmarks in cancer development [7–9]. The dependency of cancer
cells on anaerobic glycolysis, even when there is sufficient oxygen available to shunt pyruvate
into the OXPHOS pathway, is widely known as theWarburg effect [10]. Isolated defects in en-
zymes of the OXPHOS system can be a direct cause of cancer formation and the Warburg effect,
as exemplified in pheochromocytomas and paragangliomas (both with defects in complex II) or
oncocytomas (defects in complex I). Other solid tumors such as renal cell carcinomas or NBs
are characterized by a more general reduction of all OXPHOS complexes [3, 11–18].
Cancer therapies have always employed approaches targeting phenotypic characteristics of
cancer cells that render them more sensitive to a specific treatment than the rest of the body’s
cells. Similarly, in radiology, the increased uptake of glucose by cancer cells is widely employed
in 18F-fluorodeoxyglucose positron emission tomography [19]. In contrast, metabolism tar-
geted chemotherapeutics available for clinical application are mainly limited to nucleic acid
metabolism (i.e. 5-fluorouracil and methotrexate) and asparaginase treatment [20]. Therapeu-
tic targeting of the glucose-dependency of cancer cells has long focused on the (preclinical) use
of 2-deoxyglucose, a compound that is thought to block glycolytic flux. However, this once
hopeful approach has failed to translate to the clinic due to its toxicity at high doses, although
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it is still being evaluated at lower doses [21, 22]. Alternative substances that broaden the meta-
bolic targets from glycolysis to lipid- and amino acid metabolism or the tricarboxylic acid cycle
are under evaluation [20, 22–25]. Additionally, the adaptation of dietary intake to reduce side
effects and/or support cancer therapy is being revisited in pre-clinical and clinical studies.
Changing the patient’s nutrition to a ketogenic diet (KD), for instance, is thought to reduce the
growth of tumors of the central nervous system (CNS) by shifting abundant blood substrate
levels from glucose to ketone bodies and fatty acids [26–33].
KD with or without calorie restriction (CR) has for decades been part of the management of
children with intractable seizures [34]. In the pediatric population, KD is widely tolerated with-
out major side effects and has gained attention in treating adolescent and adult therapy-resis-
tant epilepsy [35]. Classic regimens (such as the Johns Hopkins protocol) offer a food-content
ratio of fats to carbohydrates and proteins of 3:1 or 4:1 (in grams). Adaptations to this basic
regimen such as combining it with variable CR or more liberal approaches such as the modified
Atkins diet are commonly applied [36, 37]. More recently, KD has been under evaluation for
alternative indications such as obesity, polycystic ovarian syndrome and degenerative diseases
of the nervous system [38]. The molecular mechanism of KD is poorly understood but data
point toward multifactorial direct and indirect metabolic adaptations, including increased mi-
tochondrial biogenesis and an altered cellular energy state [36, 39].
Preclinical data on cancers of the CNS suggest that CR and/or KD can be a potential adju-
vant approach in cancer therapy [31, 40–42]. This is supported by two case reports of patients
treated with CR-KD [43, 44], but extensive clinical evaluation is lacking. Two pilot studies of
KD in 36 adult patients showed that KD can be tolerated in patients with advanced cancers
[28, 30]. We recently reported that astrocytomas show a grade-dependent loss of mitochondri-
al respiratory chain activity, further substantiating the glucose-dependency and therefore the
likely susceptibility to KD of high-grade neuroepithelial tumors [45]. Our laboratory systemati-
cally characterized OXPHOS activities in a range of human cancers, since functional data on
the OXPHOS system in different cancer types are sparse [3, 11–18]. In the present study we
chose NB as a model tumor because NBs show a comparable reduction in OXPHOS as neuroe-
pithelial tumors of the CNS [3, 45]. Moreover, in vitro data indicate that NB cells preferentially
use glucose over ketone bodies as an energy source [46] and that ketone bodies potentially re-
duce the viability of NB cells [47]. In the context of this information, we designed a study to
evaluate the effects of dietary intervention on the growth of NB xenografts and to monitor po-
tential adaptations of the OXPHOS system.
Methods
Cell lines
The cell lines SH-SY5Y (ATCC CRL-2266) and SK-N-BE(2) (ATCC CRL-2271) were chosen
for the xenograft studies. SH-SY5Y is a TP53 wild-type, non-NMYC-amplified cell line that
shows no chromosome 1p loss of heterozygosity and is sensitive to chemotherapy. The
SK-N-BE(2) cell line shows high resistance to a wide range of chemotherapeutic agents and is
characterized by NMYC amplification, TP53mutation (p.C135F) and chromosome 1p loss of
heterozygosity [48]. Cells were grown in a 1:1 mixture of Eagle's Minimum Essential Medium
and Ham’s F12 (Sigma), supplemented with 10% fetal bovine serum (PAA), Glutamax (Gibco),
non-essential amino acids (Sigma) and penicillin/streptomycin/amphotericin (Sigma).
Animal models and sample preparation
All in vivo experiments were performed in accordance with protocols approved for this study
by the Salzburg Animal Care and Use Committee (Study approval No. 20901-TVG/44/7-
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2011). Animals were maintained under specific pathogen-free conditions and care conformed
to the Austrian Act on Animal Experimentation. Xenografts were established by subcutaneous
injection of a 200 μl matrigel (BD Bioscience) / serum-free medium suspension of NB cells
(2.7×107) on the right flank of 5- to 6-week-old female CD-1 nude mice (Charles River). After
reaching a tumor size of 150 mm3, the mice were randomized to four dietary therapy groups
(n = 8–11).
Tumor volumes were measured two times weekly using calipers and calculated with the for-
mula widthheightlength/2. Body weight, blood glucose and ketone body levels (beta-hy-
droxybutyrate) were monitored twice weekly after a two-hour fasting period in the ad libitum
fed groups or before feeding in the calorie-restricted groups. The applied technique is widely
used in clinical routine diagnostics and utilizes enzymatic based methods for quantification
(Precision Xceed, Abbott) [49–51]. After inducing sevoflurane anesthesia mice were sacrificed
by cervical dislocation at predetermined days (day 22 SH-SY5Y and day 33 SK-N-BE (2)) or
when termination criteria were met (health status, tumor ulceration or volume of 3000 mm3).
Cancer tissue was snap frozen in liquid nitrogen for OXPHOS measurements and determina-
tion of mtDNA copy number. One 0.5-cm tumor slice each was formalin-fixed and paraffin-
embedded for histological analysis.
Food composition and energy content
Mice were fed according to four different regimens: standard diet ad libitum (SD), calorie-re-
stricted standard diet (CR-SD), long chain fatty acid based ketogenic diet ad libitum (KD) and
calorie-restricted ketogenic diet (CR-KD). The metabolizable energy contents were as follows:
SD (kcal: fat 9%, protein 33% and carbohydrates 58%) and long chain fatty acid based KD (kcal:
fat 78%, protein 14% and carbohydrates 8%) (No. V1535-000 and No. S9139-E02D; Sniff Spe-
zialdiäten GmbH). A detailed list of ingredients is given in Supporting Information (S1 Table).
Diets were fortified with vitamins and mineral supplements and differed slightly between the
two diets. To determine average calorie intake, 5 mice were monitored for ad libitum feeding
for over a 5-week period (SD: mean 6.22 g ± 0.96 /d/mouse; KD: 2.7 ± 0.4 g /d/mouse). For the
CR groups, food intake was restricted to 2/3 of the corresponding ad libitum intake. This degree
of CR corresponds to those of clinical protocols for therapy-resistant epilepsy [35–37].
Extraction of 600g homogenate
Amitochondria-enriched homogenate obtained by differential centrifugation was used for en-
zyme activity measurement and western blot analysis of OXPHOS complexes. This method in-
creases specificity and is also used for the evaluation of inherited metabolic diseases [52, 53]. A
tissue disintegrator (Ultraturrax, IKA) was used to homogenize NB xenograft tissue (50–100
mg) in SEKT-extraction buffer, pH 7.6 (250 mM sucrose, 2 mM EGTA, 40 mM KCl, 20 mM
Tris-HCl). Cell membranes were then sheered with a motor-driven Teflon-glass homogenizer
(Potter S, Braun). Centrifugation of the homogenate at 600g for 10 min at 4°C yields the post-
nuclear supernatant (600g homogenate) containing the mitochondrial fraction.
Enzyme measurements
Xenograft 600g homogenate of all cases in the SH-SY5Y groups (each n = 8–11) and of repre-
sentative cases in the SK-N-BE(2) groups (each n = 5) were used for enzymatic measurements.
Activities of all individual enzymes of the OXPHOS complexes I-V) and combinations (com-
plexes I+III and complexes II+III) were measured as previously described [3, 11, 54]. In addi-
tion, CS activity was measured because it is a well-established marker of mitochondrial mass
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[55]. All quantifications were based on spectrophotometric measurements (Uvicon 922, Kon-
tron) and performed at 37°C, with the exception of complex V, 30°C.
In brief: CS (EC 2.3.3.1) activity was recorded according to Srere [56] with modifications
as noted in [3]. 10 μl of 600g homogenate was mixed with a Tris-HCl-buffered reaction mix-
ture containing: 0.1% bovine serum albumin, 0.1% Triton X-100, 0.2 mM Elman’s reagent
[5,5’-dithio-bis(2-nitrobenzoic acid)] and 0.15 mM acetyl-CoA. After recording thiolase ac-
tivity for 2 min, the CS reaction was started by addition of 0.5 mM oxaloacetate and extinc-
tion dynamics were followed at 412 nm for 8 min. Rotenone-sensitive complex I activity was
measured spectrophotometrically as NADH:decylubiquinone oxidoreductase (EC 1.6.5.3) at
340 nm. The enzyme activities of complex IV (ferrocytochrome c:oxygen oxidoreductase EC
1.9.3.1) and oligomycin-sensitive complex V ATPase (complex V, F1F0 ATP synthase, EC
3.6.3.14) were determined by using buffer conditions as previously described by Rustin et al.
[57]. The final reaction mixture for the complex V activity measurement was treated for 10
bursts with an ultra-sonifier (Bio cell disruptor 250, Branson). The complex II (succinate de-
hydrogenase, succinate:ubiquinone-oxidoreductase EC 1.3.5.1) reaction mixture was pre-in-
cubated for 10 min at 37°C. Quantification was performed for 6 min at 600 nm by
monitoring the reduction of 2,6-dichlorophenol-indophenol after addition of 10 mM succi-
nate. The reaction mixture for the measurement of the complex III activity (EC 1.10.2.2 coen-
zyme Q:cytochrome c—oxidoreductase) contained 100 μM cytochrome c and 200 μM
reduced decyl-ubiquinol. The reaction was started by addition of the 600g homogenate. After
3–4 min the reaction was inhibited by addition of 1 μM antimycin A. Antimycin A-insensi-
tive activity was subtracted from the total activity to calculate complex III activity. When not
stated otherwise, reagents were obtained from SIGMA.
Determination of the mtDNA copy number
For the determination of mtDNA copy number, proteinase K (Roche Diagnostics) treatment
was performed before extraction of total DNA from tumor tissue [58]. Quantitative real-time
PCR (iCycler, BioRad) was performed using two independent mitochondrial (m.6625_6754
and m.9910_10198) and nuclear DNA loci (POLG and RRM2B). Then, mtDNA content was
determined by calculating the ratios of the Ct values. MtDNA copy number is given as n/dip-
loid genome (the sequences of the primer-pairs 1–2 and 3–4 are given in S2 Table) [59].
Western blot analysis
600g homogenates were used for western blot analysis as described before [3]. In brief, a total
of 10 μg protein was separated on 10% acrylamide/bis-acrylamide gels and transferred to nitro-
cellulose membranes (Amersham Biosciences) using a CAPS buffer (10 mM 3-[cyclohexyla-
mino]-1-propane sulfonic acid, pH 11; 10% methanol). The following primary antibodies were
diluted in 1% western blocking reagent (Roche Diagnostics) dissolved in TBS-T: anti-GAPDH
(Glyceraldehyde-3-phosphate dehydrogenase, 1:10000, Trevigen), anti-NDUFS4 (NADH de-
hydrogenase [ubiquinone] iron-sulfur protein 4; 1:2000, Abcam), anti-SDHA (Succinate dehy-
drogenase [ubiquinone] flavoprotein subunit; 1:5000, Abcam), anti-UQCRC2 (Cytochrome b-
c1 complex subunit 2; 1:1000, Sigma), anti-MTCO2 (Cytochrome c oxidase subunit 2; 1:5000,
Abcam), anti-ATP5A (ATP synthase subunit alpha; 1:1000, Protein Tech), anti-SCOT (Succi-
nyl-CoA:3-ketoacid coenzyme A transferase 1; 1:1000, Abnova). Horseradish peroxidase-la-
beled secondary antibodies were used at a dilution of 1:1000 (Dako) and detection was carried
out with Lumi-Light POD-substrate (Roche).
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Immunohistochemical staining and analysis
OXPHOS complexes (complex I-V) and proliferation indices (Ki-67 and PHH3) were evalu-
ated in deparaffinized tumor sections of NB xenografts. For immunohistochemical staining
the following antibodies were used: anti-NDUFS4 (1:1000, Abcam), anti-SDHA (1:2000,
MitoSciences), anti-UQCRC2 (1:1500, MitoSciences), anti-MTCO2 (1:1000, MitoSciences),
anti-ATP5A (1:2000, MitoSciences), and anti-VDAC1 (Voltage-dependent anion-selective
channel protein 1; 1:3000, MitoSciences), anti-Ki-67 (1:200, Dako) and anti-PHH3 (1:500,
Cellmarque). All antibodies were diluted in Dako antibody diluent with background-reduc-
ing components (Dako). The staining and scoring procedures for the OXPHOS complexes
were performed as reported previously [17, 45]. Proliferation was scored by evaluating the
proportion of positively stained nuclei, scoring at least 500 cells per slide (Ki-67) or counting
the number of positively stained nuclei per high power field (PHH3). For all tumors at least
five representative regions were scored, magnification was 400-fold.
Statistics
Statistical analysis for continuous variables was performed by one-way ANOVA (p<0.05) and
adapted for multiple comparisons by a two-tailed Dunnett’s post-test comparing each of the
three therapy groups (CR-SD, KD and CR-KD) to the control (SD). Unless mentioned other-
wise, the results are given as mean ± SEM. Survival is expressed by the Kaplan–Meier method
and differences between groups were determined in a univariate analysis with the log-rank test.
Western blot signal intensities were quantified using Image Lab 3.0.1. Statistical analysis was
performed using Prism 5.03 (GraphPad Software) and SPSS 21 (IBM).
Results
Ketogenic diet and calorie restriction reduce tumor growth and prolong
survival in mice with NB xenografts
The effect of KD and/or CR on tumor growth was evaluated in xenograft models of two NB
cell lines (SH-SY5Y and SK-N-BE(2)) and compared to SD (n = 8–11 per diet group, Fig 1).
Whereas the SH-SY5Y cell line shows more benign characteristics and is sensitive to chemo-
therapy, the SK-N-BE(2) cell line is highly resistant to a wide range of chemotherapeutic
agents. Moreover it displays markers of poor prognosis such as NMYC amplification, TP53
mutation and chromosome 1p loss of heterozygosity [48]. Xenografts of the SH-SY5Y cell
line experienced significant growth inhibition in all three dietary intervention groups (Fig
1A). On day 19, mean tumor volume in the SD group (3541 ± 219 mm3) was significantly in-
creased compared to the CR-SD group (1884 ± 256 mm3, p = 0.001), the KD group
(1721 ± 478 mm3, p<0.001) and the CR-KD group (1199 ± 158 mm3 p<0.001). Tumor vol-
umes are given for day 19 because all except one of the tumors of the SD group reached the
maximal volume of 3000 mm3 before day 22. Survival for mice on SD at day 22 was 0% com-
pared to 75% on CR-SD (p<0.001), 50% on KD (p<0.001) and 100% on CR-KD (p<0.001)
(Fig 1C). Tumor growth in the CR diet groups was significantly inhibited in the SK-N-BE(2)
xenografts (CR-SD 1348 ± 345 mm3, p = 0.040, and CR-KD 909 ± 240 mm3 p = 0.004) when
compared to the SD group (2661 ± 418 mm3). Tumor growth in the KD group was not signif-
icantly altered (2395 ± 426 mm3, p = 0.918) (Fig 1B). Survival of mice with SK-N-BE(2) xeno-
grafts on SD at day 33 was 36% compared to 83% on CR-SD (p = 0.017), 73% on KD
(p = 0.09) and 100% on CR–KD (p<0.001) (Fig 1).
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Dietary intervention induces metabolic adaptations
Metabolic adaptation of mice to the different dietary interventions shows consistent patterns in
the SH-SY5Y and SK-N-BE(2) (Table 1) therapy groups. CR induced a significant decrease in
mean blood glucose levels when compared to SD (SH-SY5Y: CR-SD p = 0.002, CR-KD
p = 0.002; SK-N-BE(2): CR-SD p<0.001, CR-KD p<0.001). No significant blood glucose change
was detected in the KD groups (SH-SY5Y: p = 0.060; SK-N-BE(2): p = 0.092). Ketone bodies
were increased in all intervention groups compared to SD, for SH-SY5Y significant only in the
CR-KD group (p<0.001); for SK-N-BE(2) in all therapy groups (CR-SD p = 0.036, KD p<0.001,
CR-KD p<0.001). Body weight change on the last day of therapy for CR-SD was significant only
Fig 1. Ketogenic diet and calorie restriction reduce tumor growth and prolong survival in a NB xenograft model. After establishing tumors on the right
flank of CD-1nu mice, the mice were randomized to diet groups as indicated. Tumor volume was measured twice weekly. A) For SH-SY5Y xenografts at day
19, the tumors of all diet groups showed significant growth inhibition compared to the SD group (CR-SD p = 0.001, KD p<0.001, CR-KD p<0.001). B) At day
33, SK-N-BE(2) tumor growth was significantly inhibited by CR (CR-SD p = 0.040, CR-KD p = 0.004). Inhibition of tumor growth was less pronounced in the
KD group (p = 0.918). C) SH-SY5Y and D) SK-N-BE(2) show the results of Kaplan-Meier survival analysis of the corresponding treatment groups. Survival of
mice with SH-SY5Y tumors at day 22 on SD was 0% compared to 75% on CR-SD (p<0.001), 50% on KD (p<0.001) and 100% on CR-KD (p<0.001). Survival
of mice with SK-N-BE(2) xenografts at day 33 on SD was 36% compared to 83% on CR-SD (p = 0.017), 73% on KD (p = 0.09) and 100% on CR–KD
(p<0.001). A, B) Data points for tumor growth curves represent mean values ± SEM of the corresponding diet group (n = 8–11). Statistics: ANOVA (p<0.05)
followed by two-tailed Dunnett’s test correcting for multiple comparisons. C, D) Survival is expressed by the Kaplan–Meier method and differences between
groups were determined in a univariate analysis with the log-rank test. Death is coded: tumor volume above 3000 mm3, tumor ulceration or impaired health
condition. Diet groups are compared to the corresponding SD. * p0.05; ** p0.01; *** p0.001.
doi:10.1371/journal.pone.0129802.g001
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in the SH-SY5Y group (p = 0.01) and in both groups for CR-KD (SH-SY5Y: p<0.001; SK-N-BE
(2): p = 0.01). Body weight loss in the CR groups was consistently below 20%.
Proliferation indices suggest G0 or early G1 arrest as a mechanism of
reduced tumor growth
Proliferation indices Ki-67 and phospho-histone H3 (PHH3) were determined to elucidate if
growth-inhibition in the distinct dietary intervention groups is a cause of the decreased prolifer-
ative activity. The measured reduction in the fraction of cycling cells is in line with the decrease
of tumor growth in the corresponding diets (Fig 2). In the SH-SY5Y xenografts, the percentage
of Ki67-positive staining significantly decreased from 55 ± 2% in the SD group to 47 ± 1% in
the KD group (p = 0.015) and to 44 ± 2% in the CR-KD group (p = 0.001). In the SK-N-BE(2)
xenografts, Ki67 staining was significantly decreased from 75 ± 2% in the SD group to 60 ± 3%
in the CR-SD group (p<0.002) and to 63 ± 3% in the CR-KD group (p = 0.02) (Fig 2). The
PHH3 results are congruent, depicting a significant decrease in positively stained nuclei from
39 ± 1/HPF (high power field) in the SD group to 30 ± 2/HPF in the KD group (p = 0.028) and
31 ± 2/HPF in the CR-KD group (p = 0.034) of the SH-SY5Y xenografts. In the SK-N-BE(2) xe-
nografts, actively dividing cells were reduced from 47 ± 3/HPF in the SD group to 36 ± 3/HPF
in the CR-SD group (p<0.05) and 35 ± 2/HPF in the CR-KD group (p<0.05).
NB xenografts show no adaptation of mtDNA copy number or OXPHOS
enzyme activities to dietary intervention
NB tumors have more than 15-fold less mtDNA copies than normal human brain or kidney
tissue (194 ± 22 [3] versus 3448 ± 524 [45] or 2960 ± 460 [3] respectively; mean ± SEM). Even
when compared to human glioblastoma, a low-OXPHOS tumor entity, the amount of mtDNA
copies is approximately 6-fold less (1194 ± 416 [45]; mean ± SEM). Under SD, mtDNA copies
were 141 ± 24 (n = 9) in SH-SY5Y and 124 ± 11 (n = 10) in SK-N-BE(2) xenografts, matching
with data from primary NB tumors. Dietary intervention did not influence mtDNA copies
when compared to levels in the corresponding SD group (SH-SY5Y: CR-SD 141 ± 19 (n = 8),
KD 124 ± 21 (n = 7), CR-KD 111 ± 10 (n = 8). SK-N-BE(2): CR-SD 113 ± 6 (n = 7), KD
128 ± 19 (n = 11), CR-KD 135 ± 13 (n = 5); Fig 3). No significant differences between NMYC-
amplified (SK-N-BE(2)) and non-amplified (SH-SY5Y) xenografts were detected (p>0.05).
Low OXPHOS enzyme activities are compatible with in vivo data of NB tissue, supporting
the used animal model [3]. As in primary tumor tissues, respiratory chain complex II showed
the lowest levels and complex III activity is relatively stronger preserved. Especially in
SH-SY5Y xenografts also complex IV activity was stronger preserved, when compared to pri-
mary neuroblastoma tissue. Complex II enzyme activity in all diet groups of the SH-SY5Y and
Table 1. Changes in metabolic parameters of individual therapy groups.
Diet Group blood glucose [mmol/l] pa vs SD blood ketoneb [mmol/l] pa vs SD BG/BK ratioc body weight [g] pa vs SD
SD 7.9 ± 0.1 n.a. 0.5 ± 0.03 n.a. 15.80 23.15 ± 1.5 n.a.
CR-SD 6.4 ± 0.3 <0.001 0.7 ± 0.06 0.036 9.04 20.5 ± 0.6 0.108
KD 8.6 ± 0.1 0.092 0.9 ± 0.06 <0.001 9.56 25.21 ± 0.6 0.260
CR-KD 5.9 ± 0.2 <0.001 1.1 ± 0.08 <0.001 5.36 19.2 ± 0.6 0.01
aStatistics: ANOVA followed by two-tailed Dunnett´s test correcting for multiple comparisons. Diet groups are compared to the SD group. Data are given
as mean ± SEM of the average metabolic parameter [blood glucose, blood ketone (bbeta-hydroxybutyrate) or body weight].
cBlood glucose (BG, mmol/l) to blood ketone (BK, mmol/l) ratio, previously reported as Glucose Ketone Index [60]. Each group n = 11. n.a.: not applicable.
doi:10.1371/journal.pone.0129802.t001
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the SK-N-BE(2) cell line-derived xenografts did not differ significantly (Fig 2, S1 and S2 Figs).
Comprehensive enzymatic evaluation of all individual OXPHOS complexes (I-V) and citric
acid synthase (CS, indicative of mitochondrial mass) showed no significant difference when
compared to the activity of the corresponding SD group (p>0.05) (S1 and S2 Figs).
Fig 2. Proliferation indices Ki-67 (A-C) and PHH3 (D-F) suggest reduced proliferation by G0 or early G1 arrest.CR reduces proliferation in both cell
lines whereas KD caused no reduction of proliferative activity in the SK-N-BE(2) xenograft group. A) shows a representative SD Ki-67 staining pattern in
comparison to the CR-KD pattern (B) in SK-N-BE(2) tumor samples. For SH-SY5Y xenografts, PHH3 staining is depicted in D) and E) for SD and CR-KD
treatment, respectively. Results are given as mean ± SEM. Statistics: ANOVA (p <0.05) followed by Dunnett’s test correcting for multiple comparisons. Diet
groups are compared to the corresponding SD. * p0.05; ** p0.01; *** p0.001.
doi:10.1371/journal.pone.0129802.g002
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OXPHOS complex western blot analysis and immunohistochemical
staining support low enzymatic activities
Three representative tumor samples of all diet groups were evaluated for complex I-V protein
levels (Fig 4). The consistently low enzymatic activities with no significant changes in enzymat-
ic levels are supported by the OXPHOS complex protein levels on western blot analysis.
Fig 3. Evaluation of the adaptive response in mtDNA copy number and OXPHOS enzyme activities in NB xenografts to dietary intervention. Both
cell types SH-SY5Y A) and SK-N-BE(2) C) show consistent low copies of the mitochondrial genome (mean <150). Panels B) SH-SY5Y and D) SK-N-BE(2)
showmean complex II (succinate dehydrogenase) enzyme activities in xenografts of the different diet groups. Enzyme activities of all individual OXPHOS
complexes are additionally given in the S1 and S2 Figs. No significant differences were detected between the different diet groups. For the SK-N-BE(2)
xenografts, only representative samples were measured (n5). Statistics: ANOVA (p <0.05) followed by two-tailed Dunnett’s test correcting for multiple
comparisons. Diet groups are compared to the corresponding SD group. The gray bars represent control values from kidney cortex tissue as reported
previously [3].
doi:10.1371/journal.pone.0129802.g003
Inhibition of Neuroblastoma Tumor Growth by Dietary Intervention
PLOS ONE | DOI:10.1371/journal.pone.0129802 June 8, 2015 10 / 19
Quantification of loading adjusted staining intensities is given in S3 Fig. Xenografts of both cell
types show very low abundance of CII. CI, CIII and CIV showed a tendency towards increased
protein levels in the CR-KD group of the SH-SY5Y cell line. CV protein levels of the SH-SY5Y
tumors and CI of the SK-N-BE(2) tumors, did not mirror the respective enzymatic activities.
This might reflect a low enzyme activity that is not linked to the protein stability of the
analyzed subunit.
Immunohistochemical analysis of individual OXPHOS complexes (I-V) performed in the
SH-SY5Y xenografts revealed a significant decrease in complex I staining in the CR-KD group
when compared to the SD group (Fig 5; p<0.05). All other groups and complexes (II-V) were
unaltered by dietary intervention.
Succinyl-CoA:3-ketoacid coenzyme A transferase 1 (SCOT) protein
levels are low in NB xenografts
Consistent with previous reports [47, 61, 62], SCOT, the rate-limiting enzyme in ketone body
utilization, showed very low to non-detectable protein levels in western blot analysis of NB xe-
nografts, whereas SCOT is prominent in control kidney tissue. SCOT levels did not change in
response to the shift in nutrient supply induced by the different dietary interventions (S4 Fig).
Fig 4. Western blot analysis of subunits of OXPHOS complexes (CI-CV) from SH-SY5Y (A) and SK-N-BE(2) (B) xenografts. Three samples from each
diet group were loaded as indicated at the top (SD, CR-SD, KD and CR-KD). Representative subunits of CI-CV were probed as given on the left. Both cell
types show consistent strong downregulation of CII, with the other complexes being relatively more preserved at the protein level. GAPDH is shown as
loading control. As controls (cont1 and cont2), kidney cortex was used as described in [3]. Quantification of loading adjusted staining intensities is given in S3
Fig.
doi:10.1371/journal.pone.0129802.g004
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Discussion
To our knowledge, this is the first study demonstrating that targeting the metabolic phenotype
of NB by dietary intervention can influence growth of this tumor entity. In the presented xeno-
graft model KD and/or CR significantly reduced tumor growth and prolonged survival. The
observed effects support the results of tumor models of the CNS, where CR-KD showed inhibi-
tory effects on tumor growth in the pre-clinical setting [31, 40–42]. Applying KD without CR
would reduce the burden for patients undergoing adjuvant dietary therapy, and support clinical
feasibility. Further studies are needed to extend the presented data.
In line with the more pronounced resistance of the SK-N-BE(2) cell line to standard treat-
ment, xenografts also proved to be more resistant to KD in our xenograft model. We hypothe-
size that there are factors besides OXPHOS capacity that influence the sensitivity towards
dietary intervention as SK-N-BE(2) xenografts show a tendency towards lower enzymatic ac-
tivities. An explanation that might contribute to this observation is the proposed influence of
the NMYC protein on increasing glutamine uptake and utilization as an alternative substrate
[63]. Being well aware of the limitations of pre-clinical studies, we regard the proof of concept
and validation of tumor metabolic parameters as an important step to trigger further research
in this area. Although the presented model utilizes an immune-compromised host and a rather
non-physiologic tumor location, we specifically chose this model to reduce additional influ-
ences and allow extensive evaluation of the mitochondrial phenotype of tumor tissue. These
methods are in line with those of other KD mouse models [27, 64–66].
Fig 5. Immunohistochemical (IHC) staining of mitochondrial OXPHOS complexes I-V and VDAC in SH-SY5Y xenograft tumors. IHC staining of NB
sections were scored on a scale from 0–3 as described in the methods section. The CR-KD group showed a significant decrease in complex I staining. All
other evaluated parameters were unaffected by dietary changes. Voltage-dependent ion channel (VDAC) protein levels are used as a surrogate marker of
mitochondrial mass. Statistics: ANOVA (p <0.05) followed by two-tailed Dunnett’s test correcting for multiple comparisons. Diet groups are compared to the
corresponding SD group.
doi:10.1371/journal.pone.0129802.g005
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Different mechanisms might contribute to the growth inhibitory potential of KD and/or CR
on NB cancer cells observed in the presented model. A widely accepted theory is that the strong
dependency on glycolysis for anabolic processes and energy production renders cancer cells
susceptible to the decreased availability of glucose in hypovascularized tumor tissue [67–69]. In
comparison with non malignant cells, cancer cells were shown to have reduced adaptability to
the change in nutrient supply induced by KD and/or CR [31, 40–42]. Our data on the low
SCOT expression in NB cells are in line with the reported inability of cancer cells to utilize ke-
tone bodies as an energy source [61, 62]. Additionally ketone bodies might exert direct anti-
proliferative effects in NB [47]. Results of KI67 and PHH3 staining suggest that reduced prolif-
eration contributes to the observed tumor growth reduction in this model. As nutrient and en-
ergy depletion were shown to mediate cell cycle inhibition by LKB1-AMPK-pathway activation
[70, 71] and mTOR-pathway inhibition [72, 73] these pathways constitute central targets for
future investigations on the mechanisms of CR and/or KD. Besides reducing energy supply,
glucose deprivation and KD was also correlated to thioredoxin redox system imbalance by re-
ducing pentose phosphate pathway mediated NADPH production. This was linked to in-
creased reactive oxygen species and toxicity in cancer cells [27, 74, 75]. Especially with regards
to preclinical brain cancer models, also anti-angiogenic effects were reported [31, 32]. We are
convinced that investigating the molecular mechanisms leading to growth inhibition of cancer
cells in response to KD and/or CR will enhance our understanding of cancer cell biology and
help to improve treatment strategies.
Deficiency in mitochondrial respiratory chain complex II activity is a well-described charac-
teristic of familial paragangliomas and pheochromocytomas [76, 77]. Feichtinger et al. showed
in 2010 that NB, another neural crest-derived tumor entity, shares this phenotype of distinctly
low complex II activity. Although chromosomal region 1p36, where the complex II subunit-en-
coding SDHB gene maps, shows frequent loss of heterozygosity in NB, no mutation or epige-
netic inactivation in any of the known complex II subunit-encoding genes has consistently
been reported [3, 78, 79]. Additionally this low differentiated tumor entity shows a generalized
low OXPHOS activity [3]. In the present study, we demonstrated that cell line-derived NB xe-
nografts exhibit a similar OXPHOS phenotype as primary NB and might constitute a valuable
resource for investigating the metabolic phenotype of NB. Complex II is the only subunit of the
OXPHOS chain entirely encoded by the nuclear genome and is not dependent on cellular
mtDNA content. The low complex II activity therefore implies a downregulation or deficiency
of nuclear encoded OXPHOS subunits independent of the low mtDNA content. Complex II is
also the only enzyme directly linking the citric acid cycle with OXPHOS. Future studies with
this model might facilitate understanding of the regulation of mitochondrial OXPHOS com-
plex activity and expression in cancer cells.
The more generalized low mitochondrial OXPHOS activity observed in NB corresponds to
the low mtDNA copy number. This state of low mtDNA content is shared by other predomi-
nantly glycolytic cell types such as neural stem cells and glioblastoma multiforme cancer cells
and is suggested to be an important feature of low differentiation status [80, 81]. Compared to
glioblastoma, however, downregulation of mtDNA in NB is even more pronounced (approxi-
mately 6-fold) [3, 45]. Upon inducing differentiation, neural stem cells were shown to undergo
a concerted expansion of mtDNA copy number, resulting in an increase in respiratory capacity.
In comparison, glioblastoma cells showed a significantly reduced capacity to do so [80]. These
results imply a direct connection of OXPHOS activity and mtDNA content to differentiation
status and/or malignant phenotype. Besides their crucial role in cellular metabolism, mitochon-
dria acceptedly serve central functions in the induction of apoptosis under physiological condi-
tions and in cancer cells [82]. Most intriguingly the execution of this function was shown to be
dependent on preserved OXPHOS in different model systems [83–85]. Both, depleting
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mtDNA and introducing mtDNAmutations via a cybrid-cell approach, were capable of medi-
ating resistance to the induction of mitochondria-mediated apoptosis [83–86]. MtDNA con-
tent might therefore constitute a link between the low differentiation status and resistance to
apoptosis. We showed in our xenograft model that NB tumors cannot adapt mitochondrial en-
ergy metabolism to the changes in nutrient supply induced with dietary intervention. This trait
is supported by observations of sustained low OXPHOS activity, mtDNA copy number evalua-
tion and protein quantification, and was independent of NMYC status or chromosome 1p36
deletion. The molecular mechanisms underlying this low mtDNA phenotype of NB are still to
be determined. In view of the pseudo-hypoxic state that is discussed for complex II-deficient
cells, one might speculate that this phenotype causes a secondary downregulation of cellular
mtDNA replication [87]. Interestingly in vitro experiments utilizing decanoic acid (C10), a me-
dium chain fatty acid, have recently provided evidence for peroxisome proliferator-activated
receptor γ induced mitochondrial biogenesis in SH-SY5Y cells [88]. Since we did not observe
this effect in our long chain fatty acid based KD it might be of interest to further evaluate the ef-
fects of MCT-based ketogenic diets on NB tumors.
One of the main advantages of KD over developing metabolism-targeting compounds is its
ready accessibility for clinical evaluation and the lengthy past experience with clinical applica-
tion in epilepsy [34]. Especially in the pediatric population, KD may represent a facile, at-hand,
and tolerable adjunctive treatment strategy. In adult advanced-stage cancer patients, KD
showed no major side effects [28, 30]. More extensive pre-clinical evaluation and strategies to
introduce KD to NB cancer patients under controlled conditions will be mandatory to allow
possible clinical application.
Conclusions
Targeting the metabolism of cancer cells is an emerging strategy with the potential to improve
currently insufficient treatment modalities. To do so we need to validate tumor models and im-
prove characterization of native tissue with regard to cell metabolism. Here we showed that cell
line-derived NB xenografts match the OXPHOS parameters of patient-derived tumor tissue
and are therefore a valuable tool for preclinical studies. Using this model, we demonstrated
that CR and/or KD reduce NB tumor growth and that tumor cells do not express adaptive
mechanisms regarding the OXPHOS system. Therefore, we propose that KD and/or CR should
be further evaluated as a possible adjuvant therapy in patients undergoing treatment for NB.
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